Vascular fibrinolytic activity in long term treatment with second generation sulfonylurea compounds.
D001808:Blood Vessels / Q000503:physiopathology*; D002747:Chlorpropamide / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology*; D004727:Endothelium / Q000503:physiopathology; D005342:Fibrinolysis / Q000187:drug effects*; D005907:Gliclazide / Q000627:therapeutic use; D005913:Glipizide / Q000627:therapeutic use; D006801:Humans; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors / Q000378:metabolism; D015849:Plasminogen Inactivators; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D000511:alpha-Macroglobulins / Q000378:metabolism
D015849:Plasminogen Inactivators; D013453:Sulfonylurea Compounds; D000511:alpha-Macroglobulins; D010960:Plasminogen Activators; D005907:Gliclazide; D002747:Chlorpropamide; D005913:Glipizide